Terminated PHASE3 INTERVENTIONAL 2-arm NCT02134015

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)

Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

Sponsor: Daiichi Sankyo

Conditions Lung Cancer Non-small Cell Lung Cancer

Interventions Erlotinib Patritumab Placebo

Updated 11 times since 2017 Last updated: Dec 22, 2017 Started: Mar 31, 2014 Primary completion: Nov 11, 2016 Completion: Nov 11, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Pre-defined criteria for continuation were not reached

Other terminated trials from Daiichi Sankyo

See all terminations from Daiichi Sankyo

Other Lung Cancer trials with similar outcome

Browse all Lung Cancer trials

A PHASE3 clinical study on Lung Cancer and Non-small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Daiichi Sankyo and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Mar 2024 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Mar 2024 [monthly]

Terminated PHASE3

▶ Show 6 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2018 — Jun 2018 [monthly]

Terminated PHASE3
Oct 2017 — Feb 2018 [monthly]

Terminated PHASE3
Sep 2017 — Oct 2017 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo
Parexel

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alicante, Spain , Arlington, United States , Barcelona, Spain , Bend, United States , Benevento, Italy , Bologna, Italy , Brasschaat, Belgium , Brussels, Belgium , Burgos, Spain and 86 more locations